Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1608-14. doi: 10.1128/AAC.02496-15.

Abstract

Hepatitis E virus (HEV) can lead to chronic infection in solid-organ transplant patients. Ribavirin is efficient for treatment of chronically infected patients. Recently, the1634R mutation in the HEV polymerase has been associated with treatment failure. However, it is unclear if this mutation can be used as a prognostic marker of treatment outcome. We studied the prevalence of the 1634R mutation in the HEV polymerase of patients starting ribavirin therapy, the influence of the 1634R variants on the viral response, the frequency of the 1634R mutation in patients whose treatment failed, and its impact on ribavirin retreatment. We analyzed pretreatment samples from 63 solid-organ transplant patients with chronic hepatitis E using deep sequencing; 42 patients had a sustained virologic response (SVR), and 21 were non-SVR patients. We detected the 1634R variant by deep sequencing in 36.5% (23/63) of the patients (proportions, 1.3 to 100%). The 1634R variant was detected in 31.0% (13/42) of baseline plasma samples from patients with SVR and in 47.6% (10/21) in the other patients (P = 0.2). The presence of this mutation did not influence the initial decrease in viral RNA. Lastly, a second prolonged ribavirin treatment led to SVR in 70% of the patients who initially did not have SVR, despite the presence of the 1634R variant. We conclude that the presence of the 1634R variant at ribavirin initiation does not lead to absolute ribavirin resistance. Although its proportion increased in patients whose treatment failed, the presence of the 1634R variant did not compromise the response to a second ribavirin treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiviral Agents / therapeutic use*
  • Base Sequence
  • Child
  • Female
  • Genetic Markers
  • Hepatitis E / drug therapy*
  • Hepatitis E / virology
  • Hepatitis E virus / drug effects*
  • Hepatitis E virus / genetics*
  • Humans
  • Male
  • Middle Aged
  • Mutation / genetics
  • RNA Replicase / genetics*
  • RNA, Viral / genetics
  • Ribavirin / therapeutic use*
  • Sequence Analysis, RNA
  • Treatment Outcome
  • Young Adult

Substances

  • Antiviral Agents
  • Genetic Markers
  • RNA, Viral
  • Ribavirin
  • RNA Replicase

Grant support

This work was supported by Institut National de la Santé et de la Recherche Médicale. The funders had no role in study design, data collection or interpretation, or the decision to submit the work for publication.